VS-6063
Sponsors
Verastem Inc., Verastem, Inc., Michael McHale
Conditions
Malignant Pleural MesotheliomaNon-small cell lung cancerOvarian CancerRecurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Phase 1
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
RecruitingNCT03287271
Start: 2018-02-06End: 2026-04-30Target: 90Updated: 2024-08-12
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
Active, not recruitingCTIS2023-505107-24-00
Start: 2023-11-14Target: 48Updated: 2025-10-29
Phase 2
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
TerminatedNCT02004028
Start: 2013-12-12End: 2019-06-19Updated: 2024-02-20
A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)
Active, not recruitingCTIS2024-516986-35-00
Start: 2021-09-06Target: 75Updated: 2025-12-09
Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Not yet recruitingCTIS2025-524713-88-00
Target: 4Updated: 2026-06-22